Skip to main content
Home
Browse by Topic
Special Series
Conference Correspondent
NSCLC 2022 Midyear Review
Supplements
Special Issues
Multimedia
Video Library
Rapid Reactions
Home
Browse by Topic
Special Series
Conference Correspondent
NSCLC 2022 Midyear Review
Supplements
Special Issues
Multimedia
Video Library
Rapid Reactions
Subscribe
Leukemia
Ibrutinib Reduces Risk of Progression in Previously Treated CLL
Leukemia
Read More ›
Genomic Panel Likely to Be Cost-effective in AML
Leukemia
Read More ›
Novel Therapeutics Targeting CD19 and CD22 in Adult Acute Lymphoblastic Leukemia
By
Jessica K. Altman, MD
Leukemia
Read More ›
Routine Imaging Costly in B-Cell Lymphoma but Rarely Picks Up Relapse After Remission
Leukemia
Read More ›
Highlights From the 6th International Symposium on Acute Promyelocytic Leukemia
By
Lisa Raedler, PhD, RPh
Leukemia
Read More ›
Ibrutinib Tops Ofatumumab as Second-Line Therapy for CLL
Leukemia
Read More ›
Updated NCCN Guidelines for Non-Hodgkin Lymphoma Note Controversy Related to B-Cell Disease Management: Cell of Origin May Soon Influence Treatment Decisions
Leukemia
Read More ›
Molecular Diversity of CLL
By
Pranil K. Chandra, DO
Leukemia
Read More ›
Molecular Monitoring Can Provide Treatment Guidance in CML
Leukemia
Read More ›
JAK2 V617F in a Patient With AML
Leukemia
Read More ›
Page 2 of 4
1
2
3
4